Benefits of eculizumab in AQP4+neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

Palace J., Wingerchuk D. M., Fujihara K., Berthele A., Oreja-Guevara C., Kim H. J., ...Daha Fazla

MULTIPLE SCLEROSIS AND RELATED DISORDERS, cilt.47, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 47
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1016/j.msard.2020.102641
  • Dergi Adı: MULTIPLE SCLEROSIS AND RELATED DISORDERS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Anahtar Kelimeler: Neuromyelitis optica spectrum disorder, Aquaporin-4 immunoglobulin G-positive, Eculizumab, Relapse, Safety, Subgroups, NEUROMYELITIS-OPTICA, RITUXIMAB, EFFICACY, AQUAPORIN-4, DISABILITY, THERAPY, SAFETY
  • Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

Background: Antibodies to the aquaporin-4 (AQP4) water channel in neuromyelitis optica spectrum disorder (NMOSD) are reported to trigger the complement cascade, which is implicated in astrocyte damage and subsequent neuronal injury. The PREVENT study demonstrated that the terminal complement inhibitor eculizumab reduces adjudicated relapse risk in patients with anti-AQP4 immunoglobulin G-positive (AQP4+) NMOSD. The objective of this analysis was to evaluate the efficacy of eculizumab in reducing relapse risk and its safety in AQP4+ NMOSD across clinically relevant subgroups in PREVENT.